|
Univariate and multivariate logistic regression analysis of HBsAg-positive DLBCL patients |
|||
| Factor |
Median Overall survival (months) |
p-value in univariate analysis |
p-value in multivariate analysis |
|
|
|||
| Sex |
0.96 |
- |
|
| Male |
50 |
||
| Female |
55.9 |
||
| HBeAg |
- |
||
| + |
NA |
0.39 |
|
| - |
55.9 |
||
| Staging |
0.001 |
< 0.001 |
|
| I |
13 |
||
| II |
21 |
||
| III |
23 |
||
| IV |
24 |
||
| B symptom |
0.2 |
- |
|
| Yes |
NA |
||
| No |
55.9 |
||
| Age(years) |
0.21 |
- |
|
| > 60 |
NA |
||
| ≤ 60 |
55.9 |
||
| LDH |
0.17 |
- |
|
| > normal |
46.7 |
||
| normal |
55.9 |
||
| Extranodal sites |
0.47 |
- |
|
| > 1 |
37.5 |
||
| 0–1 |
55.9 |
||
| PS |
0.23 |
- |
|
| 0–1 |
55.8 |
||
| 2–4 |
NA |
||
| Radiation therapy |
0.004 |
0.093 |
|
| Yes |
NA |
||
| No |
46.7 |
||
| Pre-CT hepatic dysfunction |
0.66 |
- |
|
| Yes |
NA |
||
| No |
55.9 |
||
| Intra-CT hepatic dysfunction |
0.016 |
0.02 |
|
| Yes |
46.7 |
||
| No |
NA |
||
| Rituximab |
0.5 |
- |
|
| Yes |
NA |
||
| No |
55.9 |
||
Wang et al. BMC Cancer 2008 8:115 doi:10.1186/1471-2407-8-115 |
|||